Qube Research & Technologies LTD Scynexis Inc Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$1.4 - $2.77 $3,614 - $7,152	-2,582 Reduced 99.92%	2 $0
Q1 2024 May 14, 2024	SELL	$1.39 - $2.21 $4,557 - $7,246	-3,279 Reduced 55.93%	2,584 $3,000
Q4 2023 Feb 13, 2024	BUY	$1.56 - $2.24 $9,143 - $13,128	5,861 Added 293050.0%	5,863 $13,000
Q3 2023 Nov 13, 2023	BUY	$1.93 - $3.64 $3 - $7	2 New	2 $0
Q1 2021 May 14, 2021	SELL	$6.93 - $9.63 $168,156 - $233,671	-24,265 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$4.28 - $7.87 $128,019 - $235,399	-29,911 Reduced 55.21%	24,265 $186,000
Q3 2020 Nov 12, 2020	BUY	$4.37 - $7.48 $236,749 - $405,236	54,176 New	54,176 $239,000

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $33M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.